Related Experiment Video
Updated: Feb 23, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Selective Cytotoxicity of Manganese Nanoparticles against Human Glioblastoma Cells
I A Razumov1, E L Zav'yalov2, S Yu Troitskii3
1Federal Research Center Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia. razumov@bionet.nsc.ru.
Abstract:
Toxicity of different types of manganese nanoparticles against glioblastoma U-87MG and U-251 cells and normal human cells was studied using MTT test. The selectivity of the toxic effect of nanoparticles was evaluated as the ratio of 50% cytotoxic concentration (СС50) for human embryos fibroblasts (FECh-15) to their СС50 for tumor cells. Five of 6 samples of tested nanoparticles demonstrated selective toxic effect in vitro. Manganese oxide nanoparticles were characterized by maximum selectivity (СС50 6.9 nM and 2.1 nM for U-87MG and U-251 cells, respectively): selectivity index for glioblastoma U-87MG and U-251 cells was 29 and 95.2, respectively. Manganese oxide nanoparticles used for MRI detection of gliomas can be used for designing an oncolytic agent for the treatment of glial tumors in humans.
Insights
Manganese oxide nanoparticles show selective toxicity against glioblastoma cells, sparing normal cells. This finding supports their potential as an oncolytic agent for treating human glial tumors.
Area of Science:
- Nanomedicine
- Oncology
- Cell Biology
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- Developing targeted therapies is crucial for improving patient outcomes.
- Manganese nanoparticles are being investigated for various biomedical applications.
Purpose of the Study:
- To evaluate the in vitro toxicity and selectivity of different manganese nanoparticles against glioblastoma cells.
- To identify manganese nanoparticles with the highest selective toxicity for potential therapeutic development.
Main Methods:
- MTT assay was used to determine the cytotoxicity of manganese nanoparticles against glioblastoma U-87MG and U-251 cell lines.
- Normal human fibroblasts (FECh-15) were used as a control for assessing selectivity.
- Selectivity was quantified by the ratio of 50% cytotoxic concentration (CC50) in normal cells to tumor cells.
Main Results:
- Five out of six tested manganese nanoparticle samples exhibited selective toxicity against glioblastoma cells.
- Manganese oxide nanoparticles demonstrated the highest selectivity, with CC50 values of 6.9 nM for U-87MG and 2.1 nM for U-251 cells.
- The selectivity index for manganese oxide nanoparticles reached 29 for U-87MG and 95.2 for U-251 cells.
Conclusions:
- Manganese oxide nanoparticles possess significant selective toxicity against glioblastoma cells in vitro.
- Their established use in MRI imaging suggests a dual role in diagnosis and therapy.
- Manganese oxide nanoparticles hold promise as a basis for developing novel oncolytic agents for human glial tumors.
